Table 3.
Utilization of laboratory tests/procedures to monitor suspected resistance (N = 575)
| Percentage of physicians using tests/procedures (median-interval between tests/procedure) | Mainland China (n = 300) | South Korea (n = 100) | Taiwan (n = 100) | Thailand (n = 75) |
|---|---|---|---|---|
| Alanine aminotransferase (month) | 98 (1.4) | 100 (2.6) | 100 (1.5) | 97 (2.3) |
| HBV DNA (month) | 99 (2.8) | 92 (2.9) | 93 (5.7) | 97 (5.5) |
| Serology (month) | 89 (3.0) | 86 (3.0) | 90 (3.2) | 64 (5.8) |
| Resistance-specific testsa | 49 | 99 | 85 | 56 |
Values given are in percentages
aResistance-specific tests, such as PCR sequencing and INNO-LiPA and restriction fragment mass polymorphism